PROFESSOR ADRIAN HAYDAY
Chair of Scientific Advisory Board
Professor Adrian Hayday is a scientific founder of Adaptate and also co-founded GammaDelta Therapeutics in 2016 and brings with him a lifetime of research experience as one of the leading academics to uncover the unique properties of γδ T-cells. He began studying immunology in 1982 at MIT, where he and his colleagues first described the wholly unanticipated T-cell receptor gamma chain genes. Establishing that γδ T-cells are distinct from conventional T-cells, Professor Hayday and his colleagues demonstrated that γδ T-cells generate rapid responses to tissue dysregulation to monitor tissue integrity, rather than showing highly specific responses to pathogens, as is the case for conventional T and B cells.
Over the course of his career, Professor Hayday has authored over 200 papers, the majority of which are original research contributions. He has received many awards, including the William Clyde deVane Medal, Yale College’s highest honour for scholarship and teaching, an honorary fellowship from King’s College London, and the King’s College Business Award. He was elected to lead the British Society of Immunology (2005-09), and is an elected fellow of the Academy of Medical Sciences and of the Royal Society.
Professor Hayday has chaired the American Cancer Society grants panel; the Wellcome Trust Infection and Immunity Board, and Cancer Research UK’s science committee, and he has been advisor for many institutions including Institut Pasteur, the Max Planck Institute, and Kyoto University. In the biopharmaceutical space, he co-founded biotech company ImmunoQure, and was a member of MedImmune’s Science Advisory Board.
He trained in Biochemistry at the University of Cambridge and obtained a PhD in Molecular Virology from Imperial College London. He is currently a Professor of Immunobiology at King’s College London, a Clinical Academic Group leader at King’s Health Partners, and Group Leader at the Francis Crick Institute where he is an Assistant Research Director. He was also until 2019 the lead-investigator of a Wellcome Trust-supported, multi-centre, high-throughput phenotypic screening programme to identify novel genetic regulators of the immune system